Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.68 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.58 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.36 |
| ▸ | NNMT | P40261 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | GFER | P55789 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SIRT2 | Q8IXJ6 | 5/20 | 0.34 |
| ▸ | SIRT1 | Q96EB6 | 5/20 | 0.34 |
| ▸ | SIRT3 | Q9NTG7 | 5/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Caprolactam SCHEMBL1532933 | 0.91 | CRBN (0.67) | OR51E2CRBNFKBP5KDM4EGAA | |
| 2-Pyrrolidone SCHEMBL6849688 | 0.91 | OR51E2 (0.75) | OR51E2CRBNFKBP5KDM4EGAA | |
| 2-Pyrrolidone SCHEMBL17698402 | 0.91 | OR51E2 (0.75) | OR51E2CRBNFKBP5KDM4EGAA | |
| 2-Pyrrolidone SCHEMBL4666153 | 0.88 | OR51E2 (0.71) | OR51E2CRBNFKBP5KDM4EGAA | |
| 2-Pyrrolidone SCHEMBL2155488 | 0.88 | OR51E2 (0.71) | OR51E2CRBNFKBP5KDM4EGAA | |
| 2-Pyrrolidone SCHEMBL1458792 | 0.88 | OR51E2 (0.58) | OR51E2CRBNFKBP5KDM4EGAA | |
| 2-Pyrrolidone SCHEMBL27605240 | 0.86 | OR51E2 (0.68) | OR51E2CRBNFKBP5KDM4EGAA | |
| 2-Pyrrolidone SCHEMBL28310048 | 0.86 | OR51E2 (0.68) | OR51E2CRBNFKBP5KDM4EGAA | |
| 2-Pyrrolidone SCHEMBL1436788 | 0.85 | — | — | |
| 2-Pyrrolidone SCHEMBL27520190 | 0.85 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117253651-A | High-stability sintered copper paste and preparation method and application thereof | 北京工业大学 | 2023-12-19 | — | — | CN | claimed |
| CN-115732119-A | Metal conductive silver paste and preparation method and application thereof | 苏州思尔维纳米科技有限公司 | 2023-03-03 | — | — | CN | claimed |
| CN-111411536-B | Oxford fabric production process | 苏州市登顶纺织有限公司 | 2022-07-12 | — | — | CN | claimed |
| CN-111411536-A | Oxford fabric production process | 苏州市登顶纺织有限公司 | 2020-07-14 | — | — | CN | claimed |
| US-20040077709-A1 | Neuronal death inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-22 | — | — | US | claimed |
| CN-1368882-A | Neuronal death inhibitors | DAIICHI SEIYAKU CO (JP) | 2002-09-11 | — | — | CN | claimed |
| EP-1180366-A9 | NEURONAL DEATH INHIBITORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2002-04-24 | — | — | EP | claimed |
| EP-1180366-A1 | NEURONAL DEATH INHIBITORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2002-02-20 | — | — | EP | claimed |
| CN-1074933-C | Anti-stress, anti-impairment and anti-aging drug and process for manufacturing thereof | RIGA D (RO) | 2001-11-21 | — | — | CN | claimed |
| CN-115732119-B | Metal conductive silver paste and preparation method and application thereof | 苏州思尔维纳米科技有限公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-117567689-A | Hyperbranched slow-expansion blocking agent and preparation method thereof | 中国石油化工股份有限公司 | 2024-02-20 | — | — | CN | disclosed |
| US-11866407-B2 | Compositions and methods for inhibiting Mpro and PLpro protease activity and for preventing and treating SARS-CoV-2 infection | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2024-01-09 | — | — | US | disclosed |
| US-11866407-B2 | Compositions and methods for inhibiting Mpro and PLpro protease activity and for preventing and treating SARS-CoV-2 infection | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2024-01-09 | — | — | US | disclosed |
| CN-117253651-A | High-stability sintered copper paste and preparation method and application thereof | 北京工业大学 | 2023-12-19 | — | — | CN | disclosed |
| CN-1105357-A | Process for synthesizing alpha-pyrrolidone acetamide | UNIV BEIJING (CN) | 1995-07-19 | — | — | CN | disclosed |
| CN-1027693-C | Novel separation method of clausenamide compounds | PHARMACEUTICALS INST CHINESE A (CN) | 1995-02-22 | — | — | CN | disclosed |
| WO-1992014149-A1 | APPARATUS AND METHODS FOR USING HEMOZOIN | ARIZONA TECHNOLOGY DEVELOPMENT CORPORATION (US) | 1992-08-20 | — | — | WO | disclosed |
| CN-1012172-B | Method for separating and extracting novel clausenamide compounds | PHARMACOLOGY INST OF CAMS (CN) | 1991-03-27 | — | — | CN | disclosed |
| CN-1049345-A | The preparation method of new type amide compound with xanthic surface | PHARMACEUTICALS INST CHINESE A (CN) | 1991-02-20 | — | — | CN | disclosed |
| CN-85106973-A | Process for the preparation of a novel pharmaceutical composition of sigma-butyrolactams and pharmaceutical use thereof | — | 1987-04-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11866407-B2 | Compositions and methods for inhibiting Mpro and PLpro protease activity and for preventing and treating SARS-CoV-2 infection | ACE2, PREP, ACE | OR51E2 4174/4885CRBN 2040/4885FKBP5 724/4885 |
| US-20040077709-A1 | Neuronal death inhibitors | CASP3, CASP1, AIFM1 | OR51E2 3124/4885CRBN 1199/4885FKBP5 2059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.